ITEM VIEW

Aspalathin, a C-glucosyldihydrochalcone from rooibos improves the hypoglycemic potential of metformin in type 2 diabetic (db/db) mice

dc.contributor.authorDludla, P. V.en_ZA
dc.contributor.authorGabuza, K. B.en_ZA
dc.contributor.authorMuller, C. J. F.en_ZA
dc.contributor.authorJoubert, E.en_ZA
dc.contributor.authorLouw, J.en_ZA
dc.contributor.authorJohnson, R.en_ZA
dc.date.accessioned2020-12-21T07:30:24Z
dc.date.available2020-12-21T07:30:24Z
dc.date.issued2018-07-25
dc.identifier.citationDludla, P. V. et al. 2018. Aspalathin, a C-glucosyldihydrochalcone from rooibos improves the hypoglycemic potential of metformin in type 2 diabetic (db/db) mice. Physiological Research, 67: 813-818, doi:10.33549/physiolres.933891.
dc.identifier.issn0862-8408 (print)
dc.identifier.issn1802-9973 (online)
dc.identifier.otherdoi:10.33549/physiolres.933891
dc.identifier.urihttp://hdl.handle.net/10019.1/108973
dc.descriptionCITATION: Dludla, P. V. et al. 2018. Aspalathin, a C-glucosyldihydrochalcone from rooibos improves the hypoglycemic potential of metformin in type 2 diabetic (db/db) mice. Physiological Research, 67: 813-818, doi:10.33549/physiolres.933891.
dc.descriptionThe original publication is available at https://www.biomed.cas.cz/physiolres
dc.description.abstractENGLISH ABSTRACT: Metformin is the first line therapy of type 2 diabetics, but continued reduction of their life expectancy warrants further investigation into alternative treatment strategies. This study reports on the combinational use of metformin with aspalathin, a C-glucosyl dihydrochalcone with known glucose lowering and antioxidant properties, as an effective hypoglycemic therapy in a type 2 diabetic (db/db) mouse model. When tested as a monotherapy, a low dose of aspalathin (13 mg/kg) showed no effect, while a high dose (130 mg/kg) has already displayed a better potential than metformin in protecting against diabetes associated symptoms in db/db mice. Thus, it remains of interest to determine whether this dihydrochalcone can improve the efficacy of metformin. The results showed that this combination therapy was more effective than the use of metformin as a monotherapy in ameliorating diabetes associated symptoms, including abnormal raised fasting plasma glucose levels, impaired glucose tolerance, as well as excessively increased body weights and fat content. The treated mice also had reduced food and water consumption when compared to untreated controls, with a pronounced effect evident in the last week of treatment. Therefore, this study supports further investigations into the ameliorative effect of combination therapy of metformin and aspalathin against diabetes associated symptoms.en_ZA
dc.format.extent6 pagesen_ZA
dc.language.isoen_ZAen_ZA
dc.publisherInstitute of Physiology, The Czech Academy of Sciences
dc.subjectAspalathinen_ZA
dc.subjectMetforminen_ZA
dc.subjectCombination drug therapyen_ZA
dc.subjectDiabetes mellitusen_ZA
dc.titleAspalathin, a C-glucosyldihydrochalcone from rooibos improves the hypoglycemic potential of metformin in type 2 diabetic (db/db) miceen_ZA
dc.typeArticleen_ZA
dc.description.versionPublisher's version
dc.rights.holderInstitute of Physiology of the Czech Academy of Sciences


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

ITEM VIEW